Hepatitis C (HCV). On October 20, 2007, Bovis announced it had nominated BOV-23 as a candidate for clinical development as an orally-and intravenously administered direct antiviral for the treatment of chronic HCV infection and Influenza Type A virus. BOV-23 is designed and developed for prevention and treatment of HCV and type A Influenza virus. Currently existing chemotherapeutic agents for viral hepatitis are not sufficiently effective. An important issue is a search for effective agents. BOV-23 being an ion-exchange agent has demonstrated antiviral activity against (HCV) infection in the body. BOV-23 penetrates into all organs and tissues. Its surface is easily accessible for sorbing molecules of any size. It is highly hydrophilic. It is well wet with water, forming suspension and has high sorptive capacity. The agent, due to its proinective properties provides fast binding and elimination of endo and exotoxins as well as products of incomplete protein decay. BOV-23 has well balanced osmotic and hydrophilic properties which is also the basis for its virucidal activity.